{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:18:01Z","timestamp":1791289081708,"version":"4.3.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ijrobp.2010.08.058","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T08:13:08Z","timestamp":1288599188000},"page":"58-66","source":"Crossref","is-referenced-by-count":63,"title":["Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme"],"prefix":"10.1016","volume":"82","author":[{"given":"James J.","family":"Vredenburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James E.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leighann","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevie","family":"Threatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2010.08.058_bib1","unstructured":"American Cancer Society. Cancer Facts & Figures 2009. Factors that influence cancer rates. Atlanta, GA: American Cancer Society. p. 68."},{"key":"10.1016\/j.ijrobp.2010.08.058_bib2","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2008.21.6895","article-title":"Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial","volume":"27","author":"Grossman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib5","first-page":"1399","article-title":"Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A","volume":"9","author":"Lamszus","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1023367223575","article-title":"Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma","volume":"62","author":"Salmaggi","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1750-3639.2003.tb00013.x","article-title":"Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes","volume":"13","author":"Birner","year":"2003","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30","author":"Cobleigh","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib11","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib12","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"MacDonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib14","first-page":"107","article-title":"Novel imaging response assessment for drug therapies in recurrent malignant glioma","author":"Chang","year":"2009","journal-title":"ASCO Educational Book"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib15","first-page":"6613","article-title":"Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes","volume":"63","author":"Godard","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1535-6108(04)00118-7","article-title":"Intratumoral hypoxia, radiation resistance, and HIF-1","volume":"5","author":"Semenza","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib17","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.ijrobp.2006.11.011","article-title":"VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma","volume":"67","author":"Wachsberger","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib18","first-page":"277","article-title":"The genesis of peritumoral vasogenic brain edema and tumor cysts: A hypothetical role for tumor-derived vascular permeability factor","volume":"66","author":"Criscuolo","year":"1993","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrclinonc.2009.14","article-title":"VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer","volume":"6","author":"Gerstner","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-009-9897-1","article-title":"Glioma recurrence versus radiation necrosis: Accuracy of current imaging modalities","volume":"95","author":"Alexiou","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib22","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review","volume":"89","author":"Marras","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1538-7836.2008.02928.x","article-title":"Venous thromboembolic events and organ-specific occult cancers: A review and meta-analysis","volume":"6","author":"Iodice","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib25","first-page":"4309","article-title":"Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients","volume":"29","author":"Pan","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijrobp.2007.07.2368","article-title":"Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients","volume":"70","author":"Combs","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clineuro.2009.06.013","article-title":"Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: Single-center experience","volume":"111","author":"Jeon","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ijrobp.2010.08.058_bib28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ijrobp.2007.11.068","article-title":"Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability","volume":"71","author":"Lai","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301610032657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301610032657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:32:13Z","timestamp":1559781133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301610032657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0360301610032657"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.058","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}